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A set of currently known alleles increasing the risk for coronary
artery disease, cancer, and type 2 diabetes as identiﬁed by genome-
wide association studies was tested for compatibility with human
longevity. Here, we show that nonagenarian siblings from long-
lived families and singletons older than 85 y of age from the general
population carry the same number of disease risk alleles as young
controls. Longevity in this study population is not compromised by
the cumulative effect of this set of risk alleles for common disease.
association | aging SNP
Members of long-lived families have a lifelong survival ad-vantage (1, 2) that can be attributed to a lower risk for
coronary artery disease, cancer, and type 2 diabetes (3–5). These
observations may be explained by the presence of alleles pro-
tecting against diseases that contribute to population mortality
or the absence of alleles promoting such diseases. The latter
hypothesis can be tested now that genome-wide association
studies (GWASs) have produced a series of SNPs showing robust
associations with common diseases that are the main causes
of death.
We tested whether nonagenarians from the Leiden Longevity
Study (LLS) and octogenarians from the Leiden 85 Plus Study
carried lower total numbers of 30 major GWAS-identiﬁed dis-
ease susceptibility alleles than younger controls.
Results
Reviewing the catalog of published GWASs for coronary artery
disease, heart failure, cancer, and type 2 diabetes up to February
2009 revealed 30 SNPs in 22 disease-associated loci (Table S1).
These SNPs were investigated for their deleterious role in sur-
vival beyond 85 y of age by comparing 723 nonagenarian siblings
(mean age of 94 y) from the LLS (1), representing familial long-
lived cases, and 721 unrelated younger controls (mean age of
52 y). We also compared 979 singleton long-lived individuals older
than 85 y (mean age of 87 y) of age from the population-based
Leiden 85 Plus Study (6, 7) and 1,167 younger controls (mean age
of 41 y) from the Netherlands Twin Register (NTR) (8).
We tested whether the number of disease alleles was different
between long-lived individuals and younger controls, because the
cumulative effect of disease alleles is expected to be more pro-
nounced than that of individual SNPs, with a modest effect on
disease risk (9, 10). On average the nonagenarian siblings carried
26.7 ± 0.19 disease risk alleles, which was virtually identical to
the number carried by younger controls (27.0 ± 0.12; P = 0.127;
Fig. 1A), and the same was observed for the number carried by
sporadic long-lived subjects (26.8 ± 0.11) and younger controls
(26.8 ± 0.10; P = 0.847; Fig. 1B). The distribution of the number
of risk alleles was the same in highly aged and young subjects,
even in the tails of the distribution (Fig. 1 C and D). Similar
results were obtained when the 19 alleles associated with meta-
bolic disease or the 11 cancer-associated alleles were considered
separately. We compared 391 long-lived subjects and 409 youn-
ger controls in the 10% tails of the sum of risk allele distribution.
The carriers of the 10% upper tail of the sum of risk allele dis-
tributions did not have a decreased risk of surviving beyond 85 y
of age, because the odds ratio (OR) estimates are close to unity
(Tables S2–S4). The 95% conﬁdence interval (CI) of the OR per
extra risk allele ranges from 0.97 to 1.01. Further exploration for
different effect sizes and interacting alleles did not reveal any
evidence for a subset of alleles associating with longevity via
main effects or as interactions.
In a meta-analysis of the two cohorts, nominal signiﬁcant
associations with survival into old age were observed for seven
individual SNPs (0.023 < P < 0.046; Table S5), but none was
signiﬁcant when accounting for multiple testing (P < 0.001).
The effect on fatal disease can also be analyzed by a cross-
sectional comparison of healthy groups of different age categories
(11–13). Because disease risk alleles contribute to morbidity and
mortality, the frequencies of those risk alleles are expected to
decrease in the healthy elderly individuals of the population at
large. However, the frequency of deleterious genotypes might
increase among long-lived individuals because their protective
genotype allows disease-related genes to accumulate (12). To in-
vestigate the presence of such a buffering mechanism, we divided
all subjects and controls (n = 3,590) into 10 age groups (Table
S6) and determined the mean number of risk alleles and the allele
frequencies of the 30 SNPs in each age group. We did not observe
differences in the mean number of risk alleles (Fig. S1) or in SNP-
speciﬁc allele frequencies (Dataset S1).
Discussion
A lower genetic predisposition for disease in long-lived individ-
uals may explain why long-lived families have a delayed age of
onset and lower mortality attributable to common age-related
diseases (3–5). Therefore, our aim was to investigate whether the
absence of currently known genetic susceptibility alleles is es-
sential for survival into old age. Hence, we compared the cu-
mulative effect of alleles that have convincingly been identiﬁed
as risk factors for cardiovascular disease, type 2 diabetes, and
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cancer between long-lived individuals (aged 85 y and older) and
the middle-aged general population, in whom the disease risk
alleles are generally discovered.
Despite the fact that cardiovascular disease, cancer, and type 2
diabetes contribute to the majority of deaths in modern societies,
the cumulative effects of this set of 30 risk alleles do not restrain
the study group from surviving into old age. This observation,
together with the observations that the offspring of the nonage-
narian siblings and centenarians have a decreased prevalence of
cardiovascular disease, hypertension, and type 2 diabetes as
compared with controls (5, 14), suggests that the absence of these
disease loci does not explain the lower morbidity in the offspring.
Also, offspring of centenarians have lower mortality from cancer
despite the same cancer prevalence as compared with controls (4).
It may be possible that other factors, such as unidentiﬁed (rare)
genetic variants that associate with fatal disease, are lacking in the
study group. Alternatively, alleles protecting individuals from
cardiovascular disease, cancer, and type 2 diabetes by delaying the
onset or decreasing the severity may be prevalent in this study
group. To identify loci essential for delay of disease and survival,
a GWAS for survival into old age may be an approach by which
protective alleles could also be identiﬁed.
The sum of risk alleles has commonly been used to estimate
a cumulative effect of the risk alleles to the disease prevalence of
type 2 diabetes and cancer (9, 15–21). Previous studies reported
substantially increased risk among the upper 10% of the pop-
ulation carrying the highest number of risk alleles as compared
with the 10% with the lowest number of risk alleles [e.g., type 2
diabetes, OR= 8.7 (9); prostate cancer, OR = 9.5 (19)]. Of 20
known variants associated with type 2 diabetes, it has been esti-
mated that they would account for 5–10% of an inherited pre-
disposition for type 2 diabetes (22). The SNP sets that have been
investigated for their cumulative effect on the risk for speciﬁc
diseases in these studies overlap with the SNP set investigated in
Fig. 1. GWAS-identiﬁed disease risk alleles in nonagenarians from long-lived families and sporadic long-lived individuals. (A) Average number of risk alleles
among nonagenarian siblings and controls of the LLS. (B) Average number of risk alleles among sporadic long-lived individuals of the Leiden 85 Plus Study and
NTR controls. (C) Distribution of the number of disease risk alleles among nonagenarian siblings and controls of the LLS. (D) Distribution of the number of
disease risk alleles among sporadic long-lived participants of the Leiden 85 Plus Study and NTR controls.
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the current study. No effect of a subset of SNPs or interactions
among SNPs was detected in the current data, which are in
agreement with previous observations that additive variance often
accounts for almost all genetic variance (23). Putative associations
are thus best described with a multiplicative model in line with
previous disease-focused studies on GWAS SNP sets (9, 15–21).
An accurate estimation of a predicted cumulative effect of these
SNPs on longevity was hardly possible because the genetic asso-
ciations used for this estimation derivemostly from studies focused
on disease risk and not on the effect of disease-speciﬁc mortality.
In our study, we detected the odds of the carriers with the
highest number of risk alleles, with an OR of 0.99 (95% CI: 0.97–
1.03), to survive into old age. The boundaries of the 95% CI in
this analysis are thus close to unity, which was also the case for
the boundaries of the OR per extra risk allele. Although, in
general, the association of disease risk alleles with longevity
remains to be investigated (if all common and uncommon dis-
ease risk alleles are discovered and tested for their association
with human longevity accounting for their interaction with en-
vironmental factors), our data suggest that longevity is not likely
determined by the absence of GWAS-identiﬁed risk alleles for
cardiovascular disease, cancer, and type 2 diabetes.
Because the current GWAS-identiﬁed SNPs have a relatively
low predictive value for disease risk (24–26), it was expected that
such risk alleles only marginally affect population-wide survival.
However, the cumulative effect of cardiovascular disease, cancer,
and type 2 diabetes risk alleles, which was expected to be more
pronounced (9, 10), did not affect population survival. The ex-
tent to which disease risk attributable to the cumulative effects of
susceptibility alleles is associated with population-based mor-
tality risk should be tested in patient-based studies. Alternatively,
other genetic and environmental factors present in individuals
surviving into old age may counteract the detrimental effects of
disease susceptibility alleles.
Materials and Methods
Study Populations. All participants of the LLS, Leiden 85 Plus Study, and NTR
provided written informed consent after receiving an explanation of the
nature and consequences of the study.
LLS and Control Samples. For the LLS, nonagenarian siblings of European de-
scent were recruited together with their offspring and the partners of the
offspring, who served as population controls. Families were recruited if at
least two long-lived siblings were alive and fulﬁlled the age criterion of 89 y
or older for men and 91 y or older for women, representing less than 0.5% of
the Dutch population in 2001 (1). In total, 944 long-lived proband siblings
with a mean age of 94 y (range: 89–104 y), 1,671 offspring with a mean age
of 60 y (range: 39–81 y), and 744 partners with a mean age of 60 y (range:
36–79 y) were included.
Because we recently obtained Illumina Human660W-Quad and Human-
OmniExpress GWAS data for participants in the LLS, we were able to in-
vestigate potential substructure. First, in PLINK version 1.07 (http://pngu.
mgh.harvard.edu/purcell/plink/) (27) for 10,000 random SNPs, IBS (identity-
by-state) estimates for all pairs of subjects in the samples were computed.
Next, we performed a multidimensional scaling (mds) analysis on the N × N
matrix of genome-wide IBS pairwise distances, using the mds-plot option in
conjunction with clustering. The C1 values were plotted against C2 values to
identify clustering among the subjects and controls (Fig. S2). We conclude
that there is no substructure among the participants of the LLS to an extent
that would affect our conclusions.
Leiden 85 Plus Study. In the Leiden 85 Plus Study, two prospective population-
based cohorts consisting of inhabitants of Leiden aged 85 y and older were
followed. Between 1987 and 1989 (cohort 1), 673 subjects aged 85 y and older
of Dutch ancestry and white ethnicity were enrolled and followed up for
survival for 17 y; during this time, 672 subjects (99.9%) died. Between 1997
and 1999, 563 subjects were enrolled in the month of their 85th birthday
(cohort 2) and followed up for survival for 10 y; during this time, 453 subjects
(81%) died. Subjects were visited at their home, and there were no exclusion
criteria related to health. DNA was available from the combined cohorts for
1,245 subjects aged 85 y and older.
NTR as Population Controls. From the NTR, 1,203 unrelated participants of
European descent with mean age of 41 y (range: 18–80 y) were selected as
young population controls for whom DNA was available (8). The sub-
structure in the NTR control group has already been reported (28), and in
our study, we included the samples of Dutch descent without known family
relations (i.e., those without any substructure).
SNP Selection. Using the catalog of published GWASs published up to February
2009 (http://www.genome.gov/26525384), we reviewed 266 GWASs, 69 of
which reported on associations with coronary artery disease, heart failure,
cancer, and type 2 diabetes. These 69 GWASs reported 23 disease-associated
loci resulting from at least 2 independent GWASs, harboring 81 associated
SNPs with P < 10−4 (Table S1). For each locus, the most replicated SNP was
selected from the 81 SNPs, and, subsequently, in case of an equal number of
replications, the SNP with the lowest reported P value was selected. For 5 loci,
9 further disease-associated SNPs were selected that were in low to moderate
linkage disequilibrium (r2 < 0.80) with the most replicated SNP. Thus, 32 SNPs
were selected to be genotyped with the Sequenom iPLEX. Because 2 SNPs
failed in genotyping, 30 SNPs covering 22 loci were studied. Seventeen loci are
represented by 1 SNP, 3 loci are represented by 2 SNPs, 1 locus is represented
by 3 SNPs (8q24.21), and 1 locus is represented by 4 SNPs (9p21.3).
Genotyping. Genotyping of the selected SNPs was performed using the
Sequenom MassARRAY iPLEXGold. The average genotype call rate for
genotyped SNPs was 96.3%, and the average concordance rate was 99.7%
among 4% duplicated control samples. All 30 SNPs were in Hardy–Weinberg
equilibrium (P ≥ 0.002) among the controls.
Statistical Analysis. Single SNP analysis meta-analysis. We applied a variance-
modiﬁed Cochrane–Armitage test to take into account the relatedness be-
tween the highly aged sibling cases when computing the variances of the
scores (29). In the meta-analysis of both the LLS and Leiden 85 Plus Study/
NTR controls, the score statistics of the two studies were combined using
a ﬁxed-effects approach.
Cumulative SNP analysis. For each individual who was genotyped for all 30
SNPs, the total number of disease risk alleles was counted. The difference in
the number of disease risk alleles between long-lived subjects and population
controls was assessed by linear regression. In these analyses, the number of
risk alleles was the dependent variable and the case status was included in the
model as a categorical variable. To take into account dependencies within the
long-lived sibships of the LLS, robust SEs were used [i.e., the variance was
computed from the between-family variation (30)]. P values were also based
on these robust SEs.
Logistical regression was performed with control/long-lived status as the
outcome, study and gender as covariates, and 10% upper or lower tail as
a variable. For the estimation of the OR per extra risk allele, logistical re-
gression was performed with control/long-lived status as the outcome, study
and gender as covariates, and the sum of risk alleles as a variable. Analyses
were performed using the software package STATA/SE 11.0 (DPC Software).
Interaction analysis. Polychotomous regression (31) and logic regression (32)
were applied to the datasets of the LLS and Leiden 85 Plus/NTR controls to
identify subsets of SNPs that might have a joint effect on longevity. Cross-
validation was used for selecting the best subset of SNPs and the best
functional forms of those subsets. The two approaches are different in that
the polychotomous regression is ﬂexible in terms of inheritance modes of
the SNPs, although only pairwise interactions are considered, whereas the
logic regression is used to identify multiple interacting dominant and re-
cessive effects of SNPs.
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